Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -3.73%54 Net Cash per Share is $20.42 as of Mar. 2026, which is 1270% above its 10-year median of 1.49. GuruFocus rates UPC with a GF Score™ of 54/100 and a GF Value™ of $2.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 251 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 98.01% on this metric.
Universe Pharmaceuticals (NAS:UPC) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Universe Pharmaceuticals Net Cash per Share Related Terms
Universe Pharmaceuticals Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs NPHC, CBIH, SXTC: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Price-to-Net-Cash falls into.
Universe Pharmaceuticals Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Universe Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a Net Cash per Share of $20.42 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Universe Pharmaceuticals and its competitors. This is 1270% above median its historical median of 1.49. Over the past decade, Universe Pharmaceuticals' Net Cash per Share has ranged from 0.11 to 5.04. According to the industry distribution chart, Universe Pharmaceuticals ranks #5 out of 251 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Universe Pharmaceuticals' Net Cash per Share too high?
Universe Pharmaceuticals' current Net Cash per Share of $20.42 is 1270% above median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 5.04. The Drug Manufacturers industry median Net Cash per Share is 8.69. Universe Pharmaceuticals' value of $20.42 is 135% above this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #5 out of 251 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Net Cash per Share compare to NPHC and CBIH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #5 out of 251 companies for Net Cash per Share. This places Universe Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 8.69. Universe Pharmaceuticals' value of $20.42 is 135% above this benchmark. Historically, Universe Pharmaceuticals' own Net Cash per Share has ranged from 0.11 to 5.04 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 8.69, Universe Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.69, based on 251 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current Net Cash per Share of $20.42 is 135% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Net Cash per Share is $20.42, which is 1270% above median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.79, compared to a current price of $5.86 — trading 110% above its estimated fair value. The current Net Cash per Share is $20.42, which is 1270% above median its 10-year median of 1.49 and 135% above the Drug Manufacturers industry median of 8.69. Universe Pharmaceuticals' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Net Cash per Share is $20.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.86 is trading 110% above its estimated GF Value™ of $2.79.
GuruFocus considers Universe Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for UPC:
Net Cash per Share: $20.42 (1270% above median its 10-year median of 1.49)
GF Value™: $2.79 vs. price of $5.86 (110% above fair value)
Industry Position: 135% above the Drug Manufacturers median (#5 of 251)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
54GF Score
Get the complete analysis for UPC
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
